Pressure BioSciences' Recovery Continues, Q3 Revs up 19 Percent

The company remains in recovery mode and a restructuring program begun last year, which included layoffs and the shuttering of an R&D facility, continues. Revenue from its core PCT products was down in the third quarter despite a record number of instrument installations.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories